Safety of Newer Disease Modifying Therapies in Multiple Sclerosis

Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, Mary Rensel, Georges Jalkh, Rachelle Abi Nahed, Gabrielle Macaron, Mary Rensel

Abstract

In the past decade, the therapeutic arsenal for multiple sclerosis has expanded greatly. Newer more potent disease modifying therapies (DMTs) with varying mechanisms of actions are increasingly used early in the disease course. These newer DMTs include oral therapies (teriflunomide, dimethyl fumarate, fingolimod, siponimod, ozanimod, and cladribine) and infusion therapies (natalizumab, alemtuzumab, and ocrelizumab), and are associated with better control of disease activity and long-term outcomes in patients with MS compared to older injectable therapies (interferon beta and glatiramer acetate). However, they are associated with safety concerns and subsequent monitoring requirements. Adverse events are initially observed in phase 2 and 3 clinical trials, and further long-term data are collected in phase 3 extension studies, case series, and post-marketing reports, which highlight the need to periodically re-evaluate and adjust monitoring strategies to optimize treatment safety in an individualized approach.

Keywords: disease modifying therapies; long-term outcomes; multiple sclerosis; safety.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Díaz C., Zarco L.A., Rivera D.M. Highly active multiple sclerosis: An update. Mult. Scler. Relat. Disord. 2019;30:215–224. doi: 10.1016/j.msard.2019.01.039.
    1. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2.
    1. Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J. Neurol. Sci. 2009;277(Suppl. 1):S42–S45. doi: 10.1016/S0022-510X(09)70012-7.
    1. Bermel R.A., You X., Foulds P., Hyde R., Simon J.H., Fisher E., Rudick R.A. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta. Ann. Neurol. 2013 doi: 10.1002/ana.23758.
    1. Brown J.W.L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., Girard M., Duquette P., Trojano M., Lugaresi A., et al. Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA J. Am. Med. Assoc. 2019 doi: 10.1001/jama.2018.20588.
    1. Rotstein D., Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat. Rev. Neurol. 2019;15:287–300. doi: 10.1038/s41582-019-0170-8.
    1. Ford C., Barnett-Griness O., Alexander J., Rubinchick S., Stark Y. Twenty-five years of continuous treatment of multiple sclerosis with glatiramer acetate: Long-term safety results of the us open-label extension study. Mult. Scler. J. 2018 doi: 10.1177/1352458518798582.
    1. Bermel R.A., Rudick R.A. Interferon-beta treatment for multiple sclerosis. Neurother. J. Am. Soc. Exp. Neurother. 2007;4:633–646. doi: 10.1016/j.nurt.2007.07.001.
    1. Bornstein M.B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., Spada V., et al. A Pilot Trial of Cop 1 in Exacerbating—Remitting Multiple Sclerosis. N. Engl. J. Med. 1987 doi: 10.1056/NEJM198708133170703.
    1. Cohen J., Belova A., Selmaj K., Wolf C., Sormani M.P., Oberyé J., van den Tweel E., Mulder R., Koper N., Voortman G., et al. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2015;72:1433–1441. doi: 10.1001/jamaneurol.2015.2154.
    1. Moss B.P., Cohen J.A. The emergence of follow-on disease-modifying therapies for multiple sclerosis. Mult. Scler. J. 2019 doi: 10.1177/1352458519845106.
    1. Calabresi P.A., Kieseier B.C., Arnold D.L., Balcer L.J., Boyko A., Pelletier J., Liu S., Zhu Y., Seddighzadeh A., Hung S., et al. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): A randomised, phase 3, double-blind study. Lancet. Neurol. 2014;13:657–665. doi: 10.1016/S1474-4422(14)70068-7.
    1. Downing N.S., Aminawung J.A., Shah N.D., Krumholz H.M., Ross J.S. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005–2012. JAMA J. Am. Med. Assoc. 2014 doi: 10.1001/jama.2013.282034.
    1. Wallach J.D., Ross J.S., Naci H. The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Clin. Trials. 2018 doi: 10.1177/1740774518770648.
    1. Shepshelovich D., Tibau A., Goldvaser H., Ocana A., Seruga B., Amir E. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration between 1999 and 2014 without Randomized Controlled Trials. Mayo Clin. Proc. 2019 doi: 10.1016/j.mayocp.2018.07.027.
    1. Daclizumab withdrawn from the market worldwide. Drug Ther. Bull. 2018 doi: 10.1136/dtb.2018.4.0604.
    1. U.S. Food & Drug Administration FDA Working with Manufacturers to Withdraw Zinbryta from the Market in the United States. [(accessed on 10 April 2020)]; Available online: .
    1. Claussen M.C., Korn T. Immune mechanisms of new therapeutic strategies in MS—Teriflunomide. Clin. Immunol. 2012;142:49–56. doi: 10.1016/j.clim.2011.02.011.
    1. O’Connor P., Wolinsky J.S., Confavreux C., Comi G., Kappos L., Olsson T.P., Benzerdjeb H., Truffinet P., Wang L., Miller A., et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N. Engl. J. Med. 2011 doi: 10.1056/NEJMoa1014656.
    1. Confavreux C., O’Connor P., Comi G., Freedman M.S., Miller A.E., Olsson T.P., Wolinsky J.S., Bagulho T., Delhay J.L., Dukovic D., et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 doi: 10.1016/S1474-4422(13)70308-9.
    1. Freedman M.S. Teriflunomide in relapsing multiple sclerosis: Therapeutic utility. Ther. Adv. Chronic Dis. 2013;4:192–205. doi: 10.1177/2040622313492810.
    1. O’Connor P., Comi G., Freedman M.S., Miller A.E., Kappos L., Bouchard J.P., Lebrun-Frenay C., Mares J., Benamor M., Thangavelu K., et al. Long-term safety and efficacy of teriflunomide. Neurology. 2016 doi: 10.1212/WNL.0000000000002441.
    1. Miller A.E., Vermersch P., Kappos L., Comi G., Freedman M.S., Oh J., de Seze J., Truffinet P., Benamor M., Purvis A., et al. Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study★★. Mult. Scler. Relat. Disord. 2019 doi: 10.1016/j.msard.2019.05.014.
    1. Derouiche F. Teriflunomide-induced fatal toxic epidermal necrolysis in a patient with multiple sclerosis. Mult. Scler. 2015 doi: 10.1177/1352458515602639.
    1. Phillips J.T., Fox R.J. BG-12 in multiple sclerosis. Semin. Neurol. 2013 doi: 10.1055/s-0033-1343796.
    1. Deeks E.D. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs. 2016;76:243–254. doi: 10.1007/s40265-015-0528-1.
    1. Gold R., Kappos L., Arnold D.L., Bar-Or A., Giovannoni G., Selmaj K., Tornatore C., Sweetser M.T., Yang M., Sheikh S.I., et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 2012 doi: 10.1056/NEJMoa1114287.
    1. Fox R.J., Miller D.H., Phillips J.T., Hutchinson M., Havrdova E., Kita M., Yang M., Raghupathi K., Novas M., Sweetser M.T., et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 2012 doi: 10.1056/NEJMoa1206328.
    1. Gold R., Giovannoni G., Phillips J.T., Fox R.J., Zhang A., Marantz J.L. Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing—Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies. Neurol. Ther. 2016 doi: 10.1007/s40120-016-0042-8.
    1. Kresa-Reahl K., Repovic P., Robertson D., Okwuokenye M., Meltzer L., Mendoza J.P. Effectiveness of Delayed-release Dimethyl Fumarate on Clinical and Patient-reported Outcomes in Patients with Relapsing Multiple Sclerosis Switching From Glatiramer Acetate: RESPOND, a Prospective Observational Study. Clin. Ther. 2018 doi: 10.1016/j.clinthera.2018.10.011.
    1. Diebold M., Altersberger V., Décard B.F., Kappos L., Derfuss T., Lorscheider J. A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence. Mult. Scler. J. 2019 doi: 10.1177/1352458519852100.
    1. U.S. Food and Drug Administration Tecfidera. [(accessed on 21 October 2019)]; Available online: .
    1. Murk J.L., Nieuwkamp D.J., van Hecke W., Frijlink D.W., Killestein J., Wattjes M.P., van Oosten B.W. Fatal PML in a patient treated with compounded dimethyl fumarate with only modest lymphocytopenia. J. Neurol. Sci. 2015 doi: 10.1016/j.jns.2015.08.099.
    1. Nieuwkamp D.J., Murk J.L., van Oosten B.W. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N. Engl. J. Med. 2015;372:1474–1476. doi: 10.1056/NEJMc1413724.
    1. Rosenkranz T., Novas M., Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N. Engl. J. Med. 2015;372:1476–1478. doi: 10.1056/NEJMc1415408.
    1. Blair H.A. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Drugs. 2019;79:1965–1976. doi: 10.1007/s40265-019-01229-3.
    1. Cohen J.A., Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann. Neurol. 2011 doi: 10.1002/ana.22426.
    1. Behrangi N., Fischbach F., Kipp M. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019;8:24. doi: 10.3390/cells8010024.
    1. Tran J.Q., Hartung J.P., Tompkins C.A., Frohna P.A. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator. Clin. Pharmacol. Drug Dev. 2018 doi: 10.1002/cpdd.409.
    1. Cohen J.A., Barkhof F., Comi G., Hartung H.P., Khatri B.O., Montalban X., Pelletier J., Capra R., Gallo P., Izquierdo G., et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med. 2010 doi: 10.1056/NEJMoa0907839.
    1. Kappos L., Radue E.W., O’Connor P., Polman C., Hohlfeld R., Calabresi P., Selmaj K., Agoropoulou C., Leyk M., Zhang-Auberson L., et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med. 2010 doi: 10.1056/NEJMoa0909494.
    1. Calabresi P.A., Radue E.W., Goodin D., Jeffery D., Rammohan K.W., Reder A.T., Vollmer T., Agius M.A., Kappos L., Stites T., et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 doi: 10.1016/S1474-4422(14)70049-3.
    1. Chitnis T., Arnold D.L., Banwell B., Brück W., Ghezzi A., Giovannoni G., Greenberg B., Krupp L., Rostásy K., Tardieu M., et al. Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis. N. Engl. J. Med. 2018 doi: 10.1056/NEJMoa1800149.
    1. Kappos L., Bar-Or A., Cree B.A.C., Fox R.J., Giovannoni G., Gold R., Vermersch P., Arnold D.L., Arnould S., Scherz T., et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): A double-blind, randomised, phase 3 study. Lancet. 2018;391:1263–1273. doi: 10.1016/S0140-6736(18)30475-6.
    1. Cohen J.A., Arnold D.L., Comi G., Bar-Or A., Gujrathi S., Hartung J.P., Cravets M., Olson A., Frohna P.A., Selmaj K.W. Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): A randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 doi: 10.1016/S1474-4422(16)00018-1.
    1. Comi G., Kappos L., Selmaj K.W., Bar-Or A., Arnold D.L., Steinman L., Hartung H.P., Montalban X., Kubala Havrdová E., Cree B.A.C., et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial. Lancet Neurol. 2019 doi: 10.1016/S1474-4422(19)30239-X.
    1. Cohen J.A., Comi G., Selmaj K.W., Bar-Or A., Arnold D.L., Steinman L., Hartung H.P., Montalban X., Kubala Havrdová E., Cree B.A.C., et al. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial. Lancet Neurol. 2019 doi: 10.1016/S1474-4422(19)30238-8.
    1. Cohen J.A., Khatri B., Barkhof F., Comi G., Hartung H.P., Montalban X., Pelletier J., Stites T., Ritter S., von Rosenstiel P., et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J. Neurol. Neurosurg. Psychiatry. 2016;87:468–475. doi: 10.1136/jnnp-2015-310597.
    1. Cohen J.A., Tenenbaum N., Bhatt A., Zhang Y., Kappos L. Extended treatment with fingolimod for relapsing multiple sclerosis: The 14-year LONGTERMS study results. Ther. Adv. Neurol. Disord. 2019 doi: 10.1177/1756286419878324.
    1. Kappos L., O’Connor P., Radue E.-W., Polman C., Hohlfeld R., Selmaj K., Ritter S., Schlosshauer R., von Rosenstiel P., Zhang-Auberson L., et al. Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology. 2015 doi: 10.1212/WNL.0000000000001462.
    1. Derfuss T., Sastre-Garriga J., Montalban X., Rodegher M., Gannon G., Bezuidenhoudt M., van Hoef M., Silva D., Kappos L. The ACROSS study: Long-term efficacy of fingolimod in patients with RRMS (Follow-up at 10 years) Mult. Scler. 2016 doi: 10.1177/1352458516663086.
    1. Barrero F., Mallada-Frechin J., Martínez-Ginés M.L., Marzo M.E., Meca-Lallana V., Izquierdo G., Ara J.R., Oreja-Guevara C., Meca-Lallana J., Forero L., et al. Spanish real-world experience with fingolimod in relapsing-remitting multiple sclerosis patients: MS NEXT study. PLoS ONE. 2020 doi: 10.1371/journal.pone.0230846.
    1. Velter C., Thomas M., Cavalcanti A., Bastien M., Chochon F., Lubetzki C., Routier E., Robert C. Melanoma during fingolimod treatment for multiple sclerosis. Eur. J. Cancer. 2019;113:75–77. doi: 10.1016/j.ejca.2019.03.011.
    1. Triplett J., Kermode A.G., Corbett A., Reddel S.W. Warts and all: Fingolimod and unusual HPV-associated lesions. Mult. Scler. J. 2019 doi: 10.1177/1352458518807088.
    1. Jaafar N., Zeineddine M., Massouh J., Yamout B. Skin Warts During Fingolimod Treatment in Patients with Multiple Sclerosis. Mult. Scler. Relat. Disord. 2018 doi: 10.1016/j.msard.2018.10.101.
    1. Benedetti M.D., Marangi A., Bozzetti S., Gobbin F., Turatti M., Pea M., Gajofatto A., Mocella S. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. Mult. Scler. Relat. Disord. 2018 doi: 10.1016/j.msard.2018.04.018.
    1. Anene-Maidoh T.I., Paschall R.M., Scott Graham R. Refractory cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod: A case report. Interdiscip. Neurosurg. Adv. Tech. Case Manag. 2018 doi: 10.1016/j.inat.2017.10.005.
    1. Chong I., Wang K.Y., Lincoln C.M. Cryptococcal meningitis in a multiple sclerosis patient treated with Fingolimod: A case report and review of imaging findings. Clin. Imaging. 2019 doi: 10.1016/j.clinimag.2018.11.005.
    1. Gyang T., Hamel J., Goodman A., Samkoff L. PML-IRIS associated with fingolimod in a multiple sclerosis patient with prior immunosuppression (P2.094) Neurology. 2016;86:P2.094. doi: 10.1212/WNL.0000000000002654.
    1. Carpenter A.F., Goodwin S.J., Bornstein P.F., Larson A.J., Markus C.K. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections? Mult. Scler. 2017 doi: 10.1177/1352458516670732.
    1. Berger J.R., Cree B.A., Greenberg B., Hemmer B., Ward B.J., Dong V.M., Merschhemke M. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology. 2018 doi: 10.1212/WNL.0000000000005529.
    1. Lebrun C., Debouverie M., Vermersch P., Clavelou P., Rumbach L., de Seze J., Wiertlevski S., Defer G., Gout O., Berthier F., et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult. Scler. 2008 doi: 10.1177/1352458507083625.
    1. Hardy T.A., Chataway J. Tumefactive demyelination: An approach to diagnosis and management. J. Neurol. Neurosurg. Psychiatry. 2013;84:1047–1053. doi: 10.1136/jnnp-2012-304498.
    1. Manouchehri N., Mirmosayyeb O., Badihian S., Shaygannejad V. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod. Mult. Scler. Relat. Disord. 2018 doi: 10.1016/j.msard.2017.11.012.
    1. Killestein J., Vennegoor A., van Golde A.E.L., Bourez R.L.J.H., Wijlens M.L.B., Wattjes M.P. PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation. Case Rep. Neurol. Med. 2014 doi: 10.1155/2014/307872.
    1. Navardi S., Sahraian M.A., Naser Moghadasi A. Tumefactive demyelinating lesions after initiating fingolimod in patient with multiple sclerosis: A case report. Rev. Neurol. 2020;176:289–290. doi: 10.1016/j.neurol.2019.08.008.
    1. Navardi S., Moghadasi A.N., Sahraian M.A. A Case Report of Three Tumefactive Demyelinating Lesions after Initiating Fingolimod and Review of Articles. Mult. Scler. Relat. Disord. 2018 doi: 10.1016/j.msard.2018.10.099.
    1. Lu M.C., Shih Y.L., Hsieh T.Y., Lin J.C. Flare of hepatitis B virus after fingolimod treatment for relapsing and remitting multiple sclerosis. J. Formos. Med. Assoc. 2020;119:886–887. doi: 10.1016/j.jfma.2019.10.012.
    1. Alping P., Askling J., Burman J., Fink K., Fogdell-Hahn A., Gunnarsson M., Hillert J., Langer-Gould A., Lycke J., Nilsson P., et al. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients. Ann. Neurol. 2020 doi: 10.1002/ana.25701.
    1. Seto H., Nishimura M., Minamiji K., Miyoshi S., Mori H., Kanazawa K., Yasuda H. Disseminated cryptococcosis in a 63-year-old patient with multiple sclerosis treated with fingolimod. Intern. Med. 2016 doi: 10.2169/internalmedicine.55.7255.
    1. Ma S.B., Griffin D.W.J., Boyd S.C., Chang C.C., Wong J.S.J., Guy S.D. Cryptococcus neoformans var grubii meningoencephalitis in a patient on fingolimod for relapsing-remitting multiple sclerosis: Case report and review of published cases. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2019.101923.
    1. Achtnichts L., Obreja O., Conen A., Fux C.A., Nedeltchev K. Cryptococcal meningoencephalitis in a patient with multiple sclerosis treated with fingolimod. JAMA Neurol. 2015;72:1203–1205. doi: 10.1001/jamaneurol.2015.1746.
    1. Pham C., Bennett I., Jithoo R. Cryptococcal meningitis causing obstructive hydrocephalus in a patient on fingolimod. BMJ Case Rep. 2017 doi: 10.1136/bcr-2017-220026.
    1. Faulkner M. Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin. Drug Saf. 2015;14:1737–1748. doi: 10.1517/14740338.2015.1093620.
    1. Wills A., Fan G., Kim E., Okada C.Y., White K.P., Hopkins R.S. Primary cutaneous Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL) in a patient taking fingolimod. Dermatol. Online J. 2019;25:13030/qt2g62q2fq.
    1. Kawai H., Matsushita H., Akashi H., Furuya D., Kawakami S., Suzuki R., Moriuchi M., Ogawa Y., Kawada H., Nakamura N., et al. Peripheral T-cell lymphomas as fingolimod-associated lymphoproliferative disorder for patients with multiple sclerosis-case report with literature review. Leuk. Lymphoma. 2020;61:959–962. doi: 10.1080/10428194.2019.1691197.
    1. London F., Cambron B., Jacobs S., Delrée P., Gustin T. Glioblastoma in a fingolimod-treated multiple sclerosis patient: Causal or coincidental association? Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102012.
    1. Jeung L., Smits L.M.G., Hoogervorst E.L.J., van Oosten B.W., Frequin S.T.F.M. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.101978.
    1. Harirchian M.H., Poursadeghfard M., Sadeghipour A., Kamali H., Sarraf P. Necrotizing fungal osteomyelitis and fingolimod, 4 years after treatment with fingolimod. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102021.
    1. Samudralwar R.D., Spec A., Cross A.H. Fingolimod and cryptococcosis: Collision of immunomodulation with infectious disease. Int. J. MS Care. 2019 doi: 10.7224/1537-2073.2018-080.
    1. Muccilli A., Nehme A., Labrie M., Girard M., Odier C., Poppe A.Y. Varicella-zoster virus vasculopathy in a multiple sclerosis patient on fingolimod. J. Neurol. Sci. 2019;403:119–121. doi: 10.1016/j.jns.2019.06.025.
    1. Martinot M., Abou-Bacar A., Lamothe M., Tebacher M.A., Zadeh M.M., Dalle F., Favennec L., Costa D., Brunet J., Sellal F. Cryptosporidiosis after treatment with fingolimod: A case report and pharmacovigilance review. BMC Infect. Dis. 2020 doi: 10.1186/s12879-020-04988-7.
    1. Luna G., Alping P., Burman J., Fink K., Fogdell-Hahn A., Gunnarsson M., Hillert J., Langer-Gould A., Lycke J., Nilsson P., et al. Infection Risks among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. JAMA Neurol. 2020 doi: 10.1001/jamaneurol.2019.3365.
    1. Buiter H.J.C., Derijks L., Mulder C.J.J. Cladribine repurposed in multiple sclerosis: Making a fortune out of a generic drug. Eur. J. Hosp. Pharm. 2019;26:246–247. doi: 10.1136/ejhpharm-2019-002026.
    1. Cook S., Vermersch P., Comi G., Giovannoni G., Rammohan K., Rieckmann P., Sørensen P.S., Hamlett A., Miret M., Weiner J., et al. Safety and tolerability of cladribine tablets in multiple sclerosis: The CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study. Mult. Scler. J. 2011 doi: 10.1177/1352458510391344.
    1. Leist T.P., Comi G., Cree B.A.C., Coyle P.K., Freedman M.S., Hartung H.P., Vermersch P., Casset-Semanaz F., Scaramozza M. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): A phase 3 randomised trial. Lancet Neurol. 2014 doi: 10.1016/S1474-4422(14)70005-5.
    1. Giovannoni G., Soelberg Sorensen P., Cook S., Rammohan K., Rieckmann P., Comi G., Dangond F., Adeniji A.K., Vermersch P. Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult. Scler. J. 2018 doi: 10.1177/1352458517727603.
    1. Aruta F., Iovino A., Costa C., Manganelli F., Iodice R. Lichenoid rash: A new side effect of oral Cladribine. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102023.
    1. Freedman M.S. Insights into the Mechanisms of the Therapeutic Efficacy of Alemtuzumab in Multiple Sclerosis. J. Clin. Cell. Immunol. 2013 doi: 10.4172/2155-9899.1000152.
    1. Panitch H., Anaissie E., Cines D., DeGroot L., Dorsey F., Phillips T., Simon J., Brinar V., Demarin V., Janculjak D., et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N. Engl. J. Med. 2008 doi: 10.1056/NEJMoa0802670.
    1. Cohen J.A., Coles A.J., Arnold D.L., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., Fisher E., et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet. 2012 doi: 10.1016/S0140-6736(12)61769-3.
    1. Coles A.J., Twyman C.L., Arnold D.L., Cohen J.A., Confavreux C., Fox E.J., Hartung H.P., Havrdova E., Selmaj K.W., Weiner H.L., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet. 2012 doi: 10.1016/S0140-6736(12)61768-1.
    1. Coles A.J., Cohen J.A., Fox E.J., Giovannoni G., Hartung H.P., Havrdova E., Schippling S., Selmaj K.W., Traboulsee A., Compston D.A.S., et al. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology. 2017 doi: 10.1212/WNL.0000000000004354.
    1. Okai A.F., Amezcua L., Berkovich R.R., Chinea A.R., Edwards K.R., Steingo B., Walker A., Jacobs A.K., Daizadeh N., Williams M.J. Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study) Neurol. Ther. 2019 doi: 10.1007/s40120-019-00159-2.
    1. Rau D., Lang M., Harth A., Naumann M., Weber F., Tumani H., Bayas A. Listeria meningitis complicating alemtuzumab treatment in multiple sclerosis—report of two cases. Int. J. Mol. Sci. 2015;16:14669–14676. doi: 10.3390/ijms160714669.
    1. Holmøy T., von der Lippe H., Leegaard T.M. Listeria monocytogenes infection associated with alemtuzumab—A case for better preventive strategies. BMC Neurol. 2017 doi: 10.1186/s12883-017-0848-8.
    1. Comi G., Alroughani R., Boster A.L., Bass A.D., Berkovich R., Fernández Ó., Kim H.J., Limmroth V., Lycke J., Macdonell R.A.L., et al. Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. Mult. Scler. J. 2019 doi: 10.1177/1352458519888610.
    1. Havrdova E., Arnold D.L., Cohen J.A., Hartung H.P., Fox E.J., Giovannoni G., Schippling S., Selmaj K.W., Traboulsee A., Compston D.A.S., et al. Alemtuzumab CARE-MS i 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. Neurology. 2017 doi: 10.1212/WNL.0000000000004313.
    1. Wray S., Havrdova E., Snydman D.R., Arnold D.L., Cohen J.A., Coles A.J., Hartung H.P., Selmaj K.W., Weiner H.L., Daizadeh N., et al. Infection risk with alemtuzumab decreases over time: Pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. Mult. Scler. J. 2019 doi: 10.1177/1352458518796675.
    1. Azevedo C.J., Kutz C., Dix A., Boster A., Sanossian N., Kaplan J. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18:329–331. doi: 10.1016/S1474-4422(19)30076-6.
    1. Durand-Dubief F., Marignier R., Berthezene Y., Cottin J., Nighoghossian N., Vukusic S. Spontaneous multiple cervical artery dissections after alemtuzumab. Mult. Scler. J. 2019 doi: 10.1177/1352458519828663.
    1. Romba M.C., Newsome S.D., McArthur J.C. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis. Mult. Scler. Relat. Disord. 2019 doi: 10.1016/j.msard.2019.06.022.
    1. Myro A.Z., Bjerke G., Zarnovicky S., Holmøy T. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: A case report. BMC Pharmacol. Toxicol. 2018 doi: 10.1186/s40360-018-0267-5.
    1. Beattie W., Yan B., Sood S. Acute severe hepatitis with alemtuzumab and rechallenge after a year. J. Clin. Neurosci. 2019 doi: 10.1016/j.jocn.2018.10.055.
    1. Saarela M., Senthil K., Jones J., Tienari P.J., Soilu-Hänninen M., Airas L., Coles A., Saarinen J.T. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology. 2018 doi: 10.1212/WNL.0000000000005420.
    1. Pappolla A., Midaglia L., Boix Rodríguez C.P., Puig A.A., Lung M., Camps I.R., Castilló J., Mulero P., Vidal-Jordana A., Arrambide G., et al. Simultaneous CMV and Listeria infection following alemtuzumab treatment for multiple sclerosis. Neurology. 2019;92:296–298. doi: 10.1212/WNL.0000000000006801.
    1. Brownlee W.J., Chataway J. Opportunistic infections after alemtuzumab: New cases of norcardial infection and cytomegalovirus syndrome. Mult. Scler. 2017;23:876–877. doi: 10.1177/1352458517693440.
    1. Zappulo E., Buonomo A.R., Saccà F., Russo C.V., Scotto R., Scalia G., Nozzolillo A., Lanzillo R., Tosone G., Gentile I. Incidence and predictive risk factors of infective events in patients with multiple sclerosis treated with agents targeting CD20 and CD52 surface antigens. Open Forum Infect. Dis. 2019 doi: 10.1093/ofid/ofz445.
    1. Barton J., Hardy T.A., Riminton S., Reddel S.W., Barnett Y., Coles A., Barnett M.H. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab. Neurology. 2017;88:1004–1006. doi: 10.1212/WNL.0000000000003694.
    1. Tzartos J.S., Valsami S., Tzanetakos D., Stergiou C., Dandoulaki M., Barbarousi D., Psimenou E., Velonakis G., Stefanis L., Kilidireas K. Autoimmune hemolytic anemia, demyelinating relapse, and AQP1 antibodies after alemtuzumab infusion. Neurol. Neuroimmunol. Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000711.
    1. Bianco A., Mari P.V., Larici A.R., Lucchini M., Nociti V., Losavio F.A., de Fino C., Cicchetti G., Coraci D., Richeldi L., et al. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2019.101450.
    1. Moiola L., Guerrieri S., Pisa M., Martinelli V., Comi G. A case of listeriosis in a multiple sclerosis patient treated with alemtuzumab: A strict clinical and laboratory monitoring can help to make early diagnosis and avoid related meningitis. Mult. Scler. J. 2017 doi: 10.1177/1352458517731285.
    1. Pisa M., della Valle P., Coluccia A., Martinelli V., Comi G., D’Angelo A., Moiola L. Acquired haemophilia A as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: A case report. Mult. Scler. Relat. Disord. 2019 doi: 10.1016/j.msard.2018.11.029.
    1. Madeley J., Hodges G., Birchley A. Development of acquired haemophilia A in a patient treated with alemtuzumab for multiple sclerosis. BMJ Case Rep. 2018 doi: 10.1136/bcr-2018-226588.
    1. McCaughan G., Massey J., Sutton I., Curnow J. Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis. BMJ Case Rep. 2017 doi: 10.1136/bcr-2017-223016.
    1. Holmøy T., Fevang B., Olsen D.B., Spigset O., Bø L. Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. BMC Res. Notes. 2019 doi: 10.1186/s13104-019-4507-6.
    1. Stüve O., Bennett J.L. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri®) in inflammatory diseases. CNS Drug Rev. 2007;13:79–95. doi: 10.1111/j.1527-3458.2007.00003.x.
    1. Goodman A.D., Rossman H., Bar-Or A., Miller A., Miller D.H., Schmierer K., Lublin F., Khan O., Bormann N.M., Yang M., et al. Glance: Results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 doi: 10.1212/01.wnl.0000343880.13764.69.
    1. Kapoor R., Ho P.R., Campbell N., Chang I., Deykin A., Forrestal F., Lucas N., Yu B., Arnold D.L., Freedman M.S., et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): A phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 doi: 10.1016/S1474-4422(18)30069-3.
    1. Polman C.H., O’Connor P.W., Havrdova E., Hutchinson M., Kappos L., Miller D.H., Phillips J.T., Lublin F.D., Giovannoni G., Wajgt A., et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2006 doi: 10.1056/NEJMoa044397.
    1. Rudick R.A., Stuart W.H., Calabresi P.A., Confavreux C., Galetta S.L., Radue E.W., Lublin F.D., Weinstock-Guttman B., Wynn D.R., Lynn F., et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N. Engl. J. Med. 2006 doi: 10.1056/NEJMoa044396.
    1. Nelson S.M.L., Nguyen T.M., Mcdonald J.W.D., Macdonald J.K. Natalizumab for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2018;8:CD006097. doi: 10.1002/14651858.CD006097.pub3.
    1. Marques P.T., Kay C.S.K., Basílio F.M.A., Pinheiro R.L., Werneck L.C., Lorenzoni P.J., Scola R.H. Localized sporotrichosis during natalizumab treatment in Multiple Sclerosis. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102029.
    1. Schowinsky J., Corboy J., Vollmer T., Kleinschmidt-DeMasters B.K. Natalizumab-associated complication? First case of peripheral T cell lymphoma. Acta Neuropathol. 2012;123:751–752. doi: 10.1007/s00401-012-0967-7.
    1. Na A., Hall N., Kavar B., King J. Central nervous system lymphoma associated with natalizumab. J. Clin. Neurosci. 2014 doi: 10.1016/j.jocn.2013.10.018.
    1. Bezabeh S., Flowers C.M., Kortepeter C., Avigan M. Clinically significant liver injury in patients treated with natalizumab. Aliment. Pharmacol. Ther. 2010 doi: 10.1111/j.1365-2036.2010.04262.x.
    1. Fine A.J., Sorbello A., Kortepeter C., Scarazzini L. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin. Infect. Dis. 2013;57:849–852. doi: 10.1093/cid/cit376.
    1. Bloomgren G., Richman S., Hotermans C., Subramanyam M., Goelz S., Natarajan A., Lee S., Plavina T., Scanlon J.V., Sandrock A., et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2012 doi: 10.1056/NEJMoa1107829.
    1. Yousry T.A., Major E.O., Ryschkewitsch C., Fahle G., Fischer S., Hou J., Curfman B., Miszkiel K., Mueller-Lenke N., Sanchez E., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 2006 doi: 10.1056/NEJMoa054693.
    1. Ismail A., Kemp J., Sharrack B. Melanoma complicating treatment with Natalizumab (Tysabri) for multiple sclerosis. J. Neurol. 2009;256:1771–1772. doi: 10.1007/s00415-009-5200-9.
    1. Sabol R.A., Noxon V., Sartor O., Berger J.R., Qureshi Z., Raisch D.W., Norris L.A.B., Yarnold P.R., Georgantopoulos P., Hrushesky W.J., et al. Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) Cancer Med. 2017 doi: 10.1002/cam4.1098.
    1. Gundacker N.D., Jordan S.J., Jones B.A., Drwiega J.C., Pappas P.G. Acute cryptococcal immune reconstitution inflammatory syndrome in a patient on natalizumab. Open Forum Infect. Dis. 2016 doi: 10.1093/ofid/ofw038.
    1. Valenzuela R.M., Pula J.H., Garwacki D., Cotter J., Kattah J.C. Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab. J. Neurol. Sci. 2014 doi: 10.1016/j.jns.2014.03.007.
    1. Shenoy E.S., Mylonakis E., Hurtado R.M., Venna N. Natalizumab and HSV meningitis. J. NeuroVirol. 2011 doi: 10.1007/s13365-011-0027-4.
    1. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr. Opin. Investig. Drugs. 2008;9:1206–1215.
    1. van Meerten T., Hagenbeek A. CD20-Targeted therapy: The next generation of antibodies. Semin. Hematol. 2010 doi: 10.1053/j.seminhematol.2010.01.007.
    1. Montalban X., Hauser S.L., Kappos L., Arnold D.L., Bar-Or A., Comi G., de Seze J., Giovannoni G., Hartung H.P., Hemmer B., et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 2017 doi: 10.1056/NEJMoa1606468.
    1. Hauser S.L., Bar-Or A., Comi G., Giovannoni G., Hartung H.P., Hemmer B., Lublin F., Montalban X., Rammohan K.W., Selmaj K., et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N. Engl. J. Med. 2017 doi: 10.1056/NEJMoa1601277.
    1. Mayer L., Kappos L., Racke M.K., Rammohan K., Traboulsee A., Hauser S.L., Julian L., Köndgen H., Li C., Napieralski J., et al. Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult. Scler. Relat. Disord. 2019 doi: 10.1016/j.msard.2019.01.044.
    1. Kappos L., Li D., Calabresi P.A., O’Connor P., Bar-Or A., Barkhof F., Yin M., Leppert D., Glanzman R., Tinbergen J., et al. Ocrelizumab in relapsing-remitting multiple sclerosis: A phase 2, randomised, placebo-controlled, multicentre trial. Lancet. 2011 doi: 10.1016/S0140-6736(11)61649-8.
    1. Clifford D.B., Gass A., Richert N., Tornatore C., Vermersch P., Hughes R., Koendgen H., Gold R. Cases Reported as Progressive Multifocal Leukoencephalopathy in Ocrelizumab-Treated Patients with Multiple Sclerosis; Proceedings of the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS); Stockholm, Sweden. 11–13 September 2019.
    1. Lattanzi S., Carlini G., Acciarri M.C., Danni M., Silvestrini M. Parvovirus B19 infection in a patient with multiple sclerosis treated with ocrelizumab. Acta Neurol. Belg. 2020;120:231–232. doi: 10.1007/s13760-019-01227-y.
    1. Dudek M.I.R., Thies K., Kammenhuber S., Bösel J., Rösche J. HSV-2-encephalitis in a patient with multiple sclerosis treated with ocrelizumab. J. Neurol. 2019;266:2322–2323. doi: 10.1007/s00415-019-09391-0.
    1. Chisari C.G., Toscano S., D’Amico E., lo Fermo S., Zanghì A., Arena S., Zappia M., Patti F. An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opin. Drug Saf. 2019;18:925–948. doi: 10.1080/14740338.2019.1658741.
    1. Sunjaya D.B., Taborda C., Obeng R., Dhere T. First Case of Refractory Colitis Caused by Ocrelizumab. Inflamm. Bowel Dis. 2020 doi: 10.1093/ibd/izaa057.
    1. Nylund M., Vuorinen T., Airas L. Drug reaction with eosinophilia and systemic symptoms after ocrelizumab therapy. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2020.102058.
    1. Nicolini L.A., Canepa P., Caligiuri P., Mikulska M., Novi G., Viscoli C., Uccelli A. Fulminant Hepatitis Associated with Echovirus 25 during Treatment with Ocrelizumab for Multiple Sclerosis. JAMA Neurol. 2019;76:866–867. doi: 10.1001/jamaneurol.2019.0522.
    1. Ciardi M.R., Iannetta M., Zingaropoli M.A., Salpini R., Aragri M., Annecca R., Pontecorvo S., Altieri M., Russo G., Svicher V., et al. Reactivation of Hepatitis B Virus with Immune-Escape Mutations after Ocrelizumab Treatment for Multiple Sclerosis. Open Forum Infect. Dis. 2019 doi: 10.1093/ofid/ofy356.
    1. Darwin E., Romanelli P., Lev-Tov H. Ocrelizumab-induced psoriasiform dermatitis in a patient with multiple sclerosis. Dermatol. Online J. 2018;24:13030/qt220859qb.
    1. Ferreira V.F.M., Meredith D., Stankiewicz J.M. Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab. Neurol. Neuroimmunol. Neuroinflamm. 2019;6:e589. doi: 10.1212/NXI.0000000000000589.
    1. Zanetta C., Robotti M., Nozzolillo A., Sangalli F., Liberatore G., Nobile-Orazio E., Filippi M., Moiola L. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature. J. Neurol. Sci. 2020;409:116603. doi: 10.1016/j.jns.2019.116603.
    1. Faissner S., Schwake C., Gotzmann M., Mügge A., Schmidt S., Gold R. Endocarditis following ocrelizumab in relapsing-remitting MS. Neurol. Neuroimmunol. Neuroinflamm. 2020 doi: 10.1212/NXI.0000000000000680.
    1. Theriault M., Solomon A.J. Two cases of meningitis associated with ocrelizumab therapy. Mult. Scler. Relat. Disord. 2020 doi: 10.1016/j.msard.2019.101866.
    1. Cohen B.A. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis. Neurology. 2019 doi: 10.1212/WNL.0000000000006924.
    1. Belani R., Saven A. Cladribine in Hairy Cell Leukemia. Hematol. Oncol. Clin. N. Am. 2006;20:1109–1123. doi: 10.1016/j.hoc.2006.06.008.
    1. Hoffman M., Tallman M.S., Hakimian D., Janson D., Hogan D., Variakogis D., Kuzel T., Gordon L.I., Rai K. 2-Chlorodeoxyadenosine is an active salvage therapy in advanced indolent non-Hodgkin’s lymphoma. J. Clin. Oncol. 1994 doi: 10.1200/JCO.1994.12.4.788.
    1. Berghoff M., Schänzer A., Hildebrandt G.C., Dassinger B., Klappstein G., Kaps M., Gizewski E.R., Acker T., Grams A. Development of progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma 13 years after treatment with cladribine. Leuk. Lymphoma. 2013;54:1340–1342. doi: 10.3109/10428194.2012.740669.
    1. Alstadhaug K.B., Fykse Halstensen R., Odeh F. Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J. Clin. Virol. 2017 doi: 10.1016/j.jcv.2016.12.005.
    1. Demko S., Summers J., Keegan P., Pazdur R. FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia. Oncologist. 2008 doi: 10.1634/theoncologist.2007-0218.
    1. Hanaway M.J., Woodle E.S., Mulgaonkar S., Peddi V.R., Kaufman D.B., First M.R., Croy R., Holman J. Alemtuzumab induction in renal transplantation. N. Engl. J. Med. 2011 doi: 10.1056/NEJMoa1009546.
    1. Hall E.C., Engels E.A., Pfeiffer R.M., Segev D.L. Association of antibody induction immunosuppression with cancer after kidney transplantation. Transplantation. 2015 doi: 10.1097/TP.0000000000000449.
    1. Wendtner C.M., Ritgen M., Schweighofer C.D., Fungerle-Rowson G., Campe H., Gäger G., Eichhorst B., Busch R., Diem H., Engert A., et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) Leukemia. 2004 doi: 10.1038/sj.leu.2403354.
    1. Ishizawa K., Fukuhara N., Nakaseko C., Chiba S., Ogura M., Okamoto A., Sunaga Y., Tobinai K. Safety, efficacy and pharmacokinetics of humanized anti-CD52 monoclonal antibody alemtuzumab in Japanese patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Jpn. J. Clin. Oncol. 2017 doi: 10.1093/jjco/hyw146.
    1. O’Brien S.M., Keating M.J., Mocarski E.S. Updated guidelines on the management of cytomegalovirus reactivation on patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin. Lymphoma Myeloma. 2006 doi: 10.3816/CLM.2006.n.049.
    1. Abbi K.K.S., Rizvi S.M., Sivik J., Thyagarajan S., Loughran T., Drabick J.J. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature. Leuk. Res. 2010;34:e154–e156. doi: 10.1016/j.leukres.2010.02.036.
    1. Ontaneda D., di Capua D. Benefits versus risks of latest therapies in multiple sclerosis: A perspective review. Ther. Adv. Drug Saf. 2012;3:291–303. doi: 10.1177/2042098612462599.
    1. European Medicines Agency Use of Multiple Sclerosis Medicine Lemtrada Restricted While EMA Review is Ongoing. [(accessed on 2 May 2020)]; Available online: .
    1. Pagnini C., Arseneau K.O., Cominelli F. Natalizumab in the treatment of Crohn’s disease patients. Expert Opin. Biol. Ther. 2017 doi: 10.1080/14712598.2017.1366444.
    1. Nixon M., Menger R.P., Kalakoti P., Thakur J.D., Dossani R.H., Sharma K., Nanda A., Guthikonda B. Natalizumab-Associated Primary Central Nervous System Lymphoma. World Neurosurg. 2018;109:152–159. doi: 10.1016/j.wneu.2017.09.131.
    1. Parisinos C.A., Lees C.W., Wallace W.A.H., Satsangi J. Sarcoidosis complicating treatment with natalizumab for Crohn’s disease. Thorax. 2011 doi: 10.1136/thx.2010.155762.
    1. van Assche G., van Ranst M., Sciot R., Dubois B., Vermeire S., Noman M., Verbeeck J., Geboes K., Robberecht W., Rutgeerts P. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N. Engl. J. Med. 2005 doi: 10.1056/NEJMoa051586.
    1. Enginar A.Ü., Nur H., Gilgil E., Kaçar C. Accelerated nodulosis in a patient with rheumatoid arthritis. Arch. Rheumatol. 2019 doi: 10.5606/ArchRheumatol.2019.7020.
    1. Koller G., Cusnir I., Hall J., Ye C. Reversible alopecia areata: A little known side effect of leflunomide. Clin. Rheumatol. 2019;38:2015–2016. doi: 10.1007/s10067-019-04577-3.
    1. Wang Y., Wang F., Li H., Hao X., Shen G., Sun Y., Xia J. Toxic Epidermal Necrolysis Induced by Leflunomide in a Patient With Rheumatoid Arthritis. JCR J. Clin. Rheumatol. 2019 doi: 10.1097/RHU.0000000000000997.
    1. Machan A., Azendour H., Toufik H., Achemlal L., Boui M., Hjira N. Leflunomide-Induced Hidradenitis Suppurativa. Case Rep. Rheumatol. 2020 doi: 10.1155/2020/3549491.
    1. Tan P.S.C., Perera R. A rare case of lymphadenitis and pulmonary disease caused by Mycobacterium paraffinicum. Respirol. Case Rep. 2019 doi: 10.1002/rcr2.414.
    1. Kwok A.M.F., Morosin T. Leflunomide-induced colitis in association with enterocutaneous fistula in an immunosuppressed patient with renal transplant and rheumatoid arthritis. Clin. J. Gastroenterol. 2019 doi: 10.1007/s12328-019-00954-2.
    1. Carubbi F., Picchi G., di Bartolomeo S., Ricciardi A., Cipriani P., Marola L., Grimaldi A., Giacomelli R. Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide: A case report with emphasis on geoepidemiology. Medicine. 2019 doi: 10.1097/MD.0000000000016399.
    1. Tony H.P., Burmester G., Schulze-Koops H., Grunke M., Henes J., Kötter I., Haas J., Unger L., Lovric S., Haubitz M., et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID) Arthritis Res. Ther. 2011 doi: 10.1186/ar3337.
    1. Frampton J.E. Rituximab: A Review in Pemphigus Vulgaris. Am. J. Clin. Dermatol. 2020 doi: 10.1007/s40257-019-00497-9.
    1. Damato V., Evoli A., Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: A systematic review and meta-analysis. JAMA Neurol. 2016;73:1342–1348. doi: 10.1001/jamaneurol.2016.1637.
    1. Melsens K., Vandecasteele E., Deschepper E., Badot V., Blockmans D., Brusselle G., de Langhe E., de Pauw M., Debusschere C., Decuman S., et al. Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis. Acta Clin. Belg. Int. J. Clin. Lab. Med. 2018 doi: 10.1080/17843286.2017.1372244.
    1. Stabler S., Giovannelli J., Launay D., Cotteau-Leroy A., Heusele M., Lefèvre G., Terriou L., Lambert M., Dubucquoi S., Hachulla E., et al. Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune diseases receiving rituximab: A retrospective cohort study. Clin. Infect. Dis. 2020 doi: 10.1093/cid/ciaa127.
    1. Raffray L., Guillevin L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin. Biol. Ther. 2020 doi: 10.1080/14712598.2020.1748597.
    1. Thery-Casari C., Euvrard R., Mainbourg S., Durupt S., Reynaud Q., Durieu I., Belot A., Lobbes H., Cabrera N., Lega J.C. Severe infections in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides receiving rituximab: A meta-analysis. Autoimmun. Rev. 2020;19:102505. doi: 10.1016/j.autrev.2020.102505.
    1. Kridin K., Ahmed A.R. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun. Rev. 2020;19:102466. doi: 10.1016/j.autrev.2020.102466.
    1. Terrier B., Amoura Z., Ravaud P., Hachulla E., Jouenne R., Combe B., Bonnet C., Cacoub P., Cantagrel A., de Bandt M., et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum. 2010 doi: 10.1002/art.27541.
    1. Rastetter W., Molina A., White C.A. Rituximab: Expanding Role in Therapy for Lymphomas and Autoimmune Diseases. Annu. Rev. Med. 2004 doi: 10.1146/annurev.med.55.091902.104249.
    1. European Medicines Agency MabThera. [(accessed on 6 January 2020)]; Available online: .
    1. Chakraborty S., Tarantolo S.R., Treves J., Sambol D., Hauke R.J., Batra S.K. Progressive multifocal leukoencephalopathy in a HIV-negative patient with small lymphocytic leukemia following treatment with rituximab. Case Rep. Oncol. 2011 doi: 10.1159/000326851.
    1. Kelly D., Monaghan B., McMahon E., Watson G., Kavanagh E., O’Rourke K., McCaffrey J., Carney D. Progressive multifocal leukoencephalopathy secondary to rituximab-induced immunosuppression and the presence of John Cunningham virus: A case report and literature review. Radiol. Case Rep. 2016 doi: 10.1016/j.radcr.2016.06.003.
    1. Ishikawa Y., Kasuya T., Ishikawa J., Fujiwara M., Kita Y. A case of developing progressive multifocal leukoencephalopathy while using rituximab and mycophenolate mofetil in refractory systemic lupus erythematosus. Ther. Clin. Risk Manag. 2018 doi: 10.2147/TCRM.S167109.
    1. Felli V., di Sibio A., Anselmi M., Gennarelli A., Sucapane P., Splendiani A., Catalucci A., Marini C., Gallucci M. Progressive multifocal leukoencephalopathy following treatment with rituximab in an HIV-negative patient with non-hodgkin lymphoma: A case report and literature review. Neuroradiol. J. 2014;27:657–664. doi: 10.15274/NRJ-2014-10087.
    1. Berger J.R., Malik V., Lacey S., Brunetta P., Lehane P.B. Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: A rare event. J. NeuroVirol. 2018 doi: 10.1007/s13365-018-0615-7.
    1. Barmettler S., Ong M.S., Farmer J.R., Choi H., Walter J. Association of Immunoglobulin Levels, Infectious Risk, and Mortality with Rituximab and Hypogammaglobulinemia. JAMA Netw. Open. 2018 doi: 10.1001/jamanetworkopen.2018.4169.
    1. Oh J., O’connor P.W. Teriflunomide in the treatment of multiple sclerosis: Current evidence and future prospects. Ther. Adv. Neurol. Disord. 2014;7:239–252. doi: 10.1177/1756285614546855.
    1. Gold R., Phillips J.T., Havrdova E., Bar-Or A., Kappos L., Kim N., Thullen T., Valencia P., Oliva L., Novas M., et al. Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience. Neurol. Ther. 2015 doi: 10.1007/s40120-015-0033-1.
    1. Guarnera C., Bramanti P., Mazzon E. Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis. Drug Des. Dev. Ther. 2017;11:2193–2207. doi: 10.2147/DDDT.S137572.
    1. Lee J.M., Han M.H. Patient experience and practice trends in multiple sclerosis—Clinical utility of fingolimod. Patient Prefer. Adherence. 2015;9:685–693. doi: 10.2147/PPA.S57354.
    1. Ward M.D., Jones D.E., Goldman M.D. Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis. Expert Opin. Drug Saf. 2014;13:989–998. doi: 10.1517/14740338.2014.920820.
    1. Aramideh Khouy R., Karampoor S., Keyvani H., Bokharaei-Salim F., Monavari S.H., Taghinezhad S., Etemadifar M., Esghaei M. The frequency of varicella-zoster virus infection in patients with multiple sclerosis receiving fingolimod. J. Neuroimmunol. 2019 doi: 10.1016/j.jneuroim.2018.12.009.
    1. Kappos L., Cohen J., Collins W., de Vera A., Zhang-Auberson L., Ritter S., von Rosenstiel P., Francis G. Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. Mult. Scler. Relat. Disord. 2014;3:494–504. doi: 10.1016/j.msard.2014.03.002.
    1. Evdoshenko E.P., Neofidov N.A., Bakhtiyarova K.Z., Davydovskaya M.V., Kairbekova E.I., Kolontareva Y.M., Malkova N.A., Odinak M.M., Popova E.V., Sazonov D.V., et al. The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis. Zhurnal Nevrol. I Psikhiatrii Im. S.S. Korsakova. 2019 doi: 10.17116/jnevro201911910110.
    1. Derfuss T., Mehling M., Papadopoulou A., Bar-Or A., Cohen J.A., Kappos L. Advances in oral immunomodulating therapies in relapsing multiple sclerosis. Lancet Neurol. 2020;19:336–347. doi: 10.1016/S1474-4422(19)30391-6.
    1. Rasche L., Paul F. Ozanimod for the treatment of relapsing remitting multiple sclerosis. Expert Opin. Pharmacother. 2018 doi: 10.1080/14656566.2018.1540592.
    1. Cook S., Leist T., Comi G., Montalban X., Giovannoni G., Nolting A., Hicking C., Galazka A., Sylvester E. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult. Scler. Relat. Disord. 2019 doi: 10.1016/j.msard.2018.11.021.
    1. Avasarala J. The TOUCH program and natalizumab: Fundamental flaw in patient protection. F1000Research. 2016 doi: 10.12688/f1000research.7513.2.
    1. Clerico M., Artusi C.A., di Liberto A., Rolla S., Bardina V., Barbero P., de Mercanti S.F., Durelli L. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Expert Opin. Drug Saf. 2017 doi: 10.1080/14740338.2017.1346082.
    1. Fernandez O. Best practice in the use of natalizumab in multiple sclerosis. Ther. Adv. Neurol. Disord. 2013;6:69–79. doi: 10.1177/1756285612470401.
    1. McGuigan C., Craner M., Guadagno J., Kapoor R., Mazibrada G., Molyneux P., Nicholas R., Palace J., Pearson O.R., Rog D., et al. Stratification and monitoring of natalizumabassociated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J. Neurol. Neurosurg. Psychiatry. 2016 doi: 10.1136/jnnp-2015-311100.
    1. Devonshire V., Phillips R., Wass H., da Roza G., Senior P. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: Practical recommendations. J. Neurol. 2018;265:2494–2505. doi: 10.1007/s00415-018-8822-y.
    1. Bittner S., Ruck T., Wiendl H., Grauer O.M., Meuth S.G. Targeting B cells in relapsing-remitting multiple sclerosis: From pathophysiology to optimal clinical management. Ther. Adv. Neurol. Disord. 2017 doi: 10.1177/1756285616666741.
    1. European Medicines Agency Movectro: Withdrawal of the Marketing Authorization Application. [(accessed on 16 May 2020)]; Available online: .
    1. Pakpoor J., Disanto G., Altmann D.R., Pavitt S., Turner B.P., Marta M., Juliusson G., Baker D., Chataway J., Schmierer K. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol. Neuroimmunol. Neuroinflamm. 2015;2:e158. doi: 10.1212/NXI.0000000000000158.
    1. Mulero P., Midaglia L., Montalban X. Ocrelizumab: A new milestone in multiple sclerosis therapy. Ther. Adv. Neurol. Disord. 2018 doi: 10.1177/1756286418773025.
    1. Farrell K., Bennett D.L., Schwartz T.L. Screening for Breast Cancer: What You Need to Know. MO. Med. 2020;117:133–135.
    1. Wormser D., Evershed J., Ferreira G., Stokmaier D., Wang Q., Ziemseen T. Verismo: A post-marketing safety study to determine the incidence of all malignancies and breast cancer in patients with multiple sclerosis treated with ocrelizumab; Proceedings of the 71st American Academy of Neurology (AAN) Annual Meeting; Philadelphia, PA, USA. 4–10 May 2019.
    1. Bibbins-Domingo K., Grossman D.C., Curry S.J., Davidson K.W., Ebell M., Epling J.W., García F.A.R., Gillman M.W., Kemper A.R., Krist A.H., et al. Screening for skin cancer US preventive services task force recommendation statement. JAMA J. Am. Med. Assoc. 2016 doi: 10.1001/jama.2016.8465.
    1. Curry S.J., Krist A.H., Owens D.K., Barry M.J., Caughey A.B., Davidson K.W., Doubeni C.A., Epling J.W., Kemper A.R., Kubik M., et al. Screening for cervical cancer us preventive services task force recommendation statement. JAMA J. Am. Med. Assoc. 2018 doi: 10.1001/jama.2018.10897.
    1. Macaron G., Ontaneda D. Clinical commentary on “Warts and all: Fingolimod and unusual HPV associated lesions”. Mult. Scler. J. 2019 doi: 10.1177/1352458518813109.
    1. Chun J., Hartung H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010;33:91–101. doi: 10.1097/WNF.0b013e3181cbf825.
    1. Grebenciucova E., Reder A.T., Bernard J.T. Immunologic mechanisms of fingolimod and the role of immunosenescence in the risk of cryptococcal infection: A case report and review of literature. Mult. Scler. Relat. Disord. 2016 doi: 10.1016/j.msard.2016.07.015.
    1. Zoehner G., Miclea A., Salmen A., Kamber N., Diem L., Friedli C., Bagnoud M., Ahmadi F., Briner M., Sédille-Mostafaie N., et al. Reduced serum immunoglobulin G concentrations in multiple sclerosis: Prevalence and association with disease-modifying therapy and disease course. Ther. Adv. Neurol. Disord. 2019;12:1756286419878340. doi: 10.1177/1756286419878340.
    1. Marcinno A., Marnetto F., Valentino P., Martire S., Balbo A., Drago A., Leto M., Capobianco M., Panzica G., Bertolotto A. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol. Neuroimmunol. Neuroinflamm. 2018 doi: 10.1212/NXI.0000000000000498.
    1. Christou E.A.A., Giardino G., Worth A., Ladomenou F. Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab. Int. Rev. Immunol. 2017;36:352–359. doi: 10.1080/08830185.2017.1346092.
    1. Barmettler S., Price C. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab—for how long? J. Allergy Clin. Immunol. 2015 doi: 10.1016/j.jaci.2015.06.035.
    1. Rubbert-Roth A., Tak P.P., Zerbini C., Tremblay J.L., Carreño L., Armstrong G., Collinson N., Shaw T.M. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR) Rheumatology. 2010 doi: 10.1093/rheumatology/keq116.
    1. Vital E.M., Dass S., Rawstron A.C., Buch M.H., Goëb V., Henshaw K., Ponchel F., Emery P. Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re-treatment. Arthritis Rheum. 2010 doi: 10.1002/art.27359.
    1. Trouvin A.P., Jacquot S., Grigioni S., Curis E., Dedreux I., Roucheux A., Boulard H., Vittecoq O., le Loët X., Boyer O., et al. Usefulness of monitoring of B cell depletion in rituximab-treated rheumatoid arthritis patients in order to predict clinical relapse: A prospective observational study. Clin. Exp. Immunol. 2015 doi: 10.1111/cei.12481.
    1. Cambridge G., Leandro M.J., Edwards J.C.W., Ehrenstein M.R., Salden M., Bodman-Smith M., Webster A.D.B. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003 doi: 10.1002/art.11181.
    1. Leandro M.J., Cambridge G., Ehrenstein M.R., Edwards J.C.W. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006 doi: 10.1002/art.21617.
    1. Roll P., Dörner T., Tony H.P. Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and b cell subset regeneration after repeated treatment. Arthritis Rheum. 2008 doi: 10.1002/art.23473.
    1. Kim S.H., Huh S.Y., Lee S.J., Joung A.R., Kim H.J. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013 doi: 10.1001/jamaneurol.2013.3071.
    1. Kim S.H., Jeong I.H., Hyun J.W., Joung A.R., Jo H.J., Hwang S.H., Yun S., Joo J., Kim H.J. Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol. 2015 doi: 10.1001/jamaneurol.2015.1276.
    1. Ellrichmann G., Bolz J., Peschke M., Duscha A., Hellwig K., Lee D.H., Linker R.A., Gold R., Haghikia A. Peripheral CD19 + B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. J. Neurol. 2019 doi: 10.1007/s00415-018-9092-4.
    1. Fox E.J., Buckle G.J., Singer B., Singh V., Boster A. Lymphopenia and DMTs for relapsing forms of MS: Considerations for the treating neurologist. Neurol. Clin. Pract. 2019;9:53–63. doi: 10.1212/CPJ.0000000000000567.
    1. Brück W., Gold R., Lund B.T., Oreja-Guevara C., Prat A., Spencer C.M., Steinman L., Tintoré M., Vollmer T.L., Weber M.S., et al. Therapeutic decisions in multiple sclerosis moving beyond efficacy. JAMA Neurol. 2013;70:1315–1324. doi: 10.1001/jamaneurol.2013.3510.
    1. Zhang X., Tao Y., Chopra M., Ahn M., Marcus K.L., Choudhary N., Zhu H., Markovic-Plese S. Differential Reconstitution of T Cell Subsets following Immunodepleting Treatment with Alemtuzumab (Anti-CD52 Monoclonal Antibody) in Patients with Relapsing–Remitting Multiple Sclerosis. J. Immunol. 2013 doi: 10.4049/jimmunol.1301926.
    1. Coles A.J., Cox A., le Page E., Jones J., Trip S.A., Deans J., Seaman S., Miller D.H., Hale G., Waldmann H., et al. The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy. J. Neurol. 2006 doi: 10.1007/s00415-005-0934-5.
    1. Cossburn M.D., Harding K., Ingram G., El-Shanawany T., Heaps A., Pickersgill T.P., Jolles S., Robertson N.P. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology. 2013 doi: 10.1212/WNL.0b013e31827b5927.
    1. Cox A.L., Thompson S.A.J., Jones J.L., Robertson V.H., Hale G., Waldmann H., Compston D.A.S., Coles A.J. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur. J. Immunol. 2005 doi: 10.1002/eji.200535075.
    1. Bierhansl L., Ruck T., Pfeuffer S., Gross C.C., Wiendl H., Meuth S.G. Signatures of immune reprogramming in anti-CD52 therapy of MS: Markers for risk stratification and treatment response. Neurol. Res. Pract. 2019 doi: 10.1186/s42466-019-0045-x.
    1. Rolla S., Maglione A., de Mercanti S.F., Clerico M. The Meaning of Immune Reconstitution after Alemtuzumab Therapy in Multiple Sclerosis. Cells. 2020;9:1396. doi: 10.3390/cells9061396.
    1. Moss B.P., Rensel M.R., Hersh C.M. Wellness and the Role of Comorbidities in Multiple Sclerosis. Neurotherapeutics. 2017;14:999–1017. doi: 10.1007/s13311-017-0563-6.
    1. Tallantyre E.C., Causon E.G., Harding K.E., Pickersgill T.P., Robertson N.P. The aetiology of acute neurological decline in multiple sclerosis: Experience from an open-access clinic. Mult. Scler. J. 2015 doi: 10.1177/1352458514538333.
    1. Macaron G., Cohen J.A. Integrating multiple sclerosis guidelines into practice. Lancet Neurol. 2018;17:658–660. doi: 10.1016/S1474-4422(18)30248-5.
    1. Ontaneda D., Tallantyre E., Kalincik T., Planchon S.M., Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18:973–980. doi: 10.1016/S1474-4422(19)30151-6.
    1. Barclay K., Carruthers R., Traboulsee A., Bass A.D., LaGanke C., Bertolotto A., Boster A., Celius E.G., de Seze J., Cruz D.D., et al. Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. Front. Neurol. 2019 doi: 10.3389/fneur.2019.00253.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir